Navigation Links
Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer

tumor response. The most common severe (Grade 3 or higher) side effects were neutropenia (20.8%), asthenia (16.7%), febrile neutropenia (12.5%), atrial fibrillation (8.3%) and hypotension (8.3%).

"These initial results are encouraging because a relatively low proportion of patients are experiencing disease progression at this time when treated with Xcytrin plus chemotherapy consistent with the synergistic effects we observed in preclinical and early clinical studies," said Richard A. Miller, M.D., president and CEO of Pharmacyclics. "Along with the activity seen in our single agent trial for second-line treatment of non-small cell lung cancer reported last month at ASCO, these data continue to support Xcytrin's potential role in this underserved cancer and further inform the design of our pivotal Phase 3 trial in this indication, which we plan to begin in the first half of 2008."

A New Drug Application for use of Xcytrin in combination with whole brain radiation therapy for treatment of brain metastases from NSCLC was filed with the U.S. Food and Drug Administration in April 2007.

About Non-Small Cell Lung Cancer

The American Cancer Society estimates that there will be more than 213,000 new cases of lung cancer in the United States in 2007. Lung cancer is the leading cause of cancer death, and accounts for over 160,000 deaths in the United States each year. The most common form of lung cancer, non-small cell, is incurable in advanced stages. Lung cancer frequently spreads to other body parts, including the brain.

Xcytrin in Second-Line Lung Cancer

Pharmacyclics is developing Xcytrin as an anti-cancer agent with a novel mechanism of action that is designed to selectively concentrate in tumors and induce apoptosis (programmed cell death). Xcytrin is a redox-active drug that has been shown to disrupt redox-dependent pathways in cells and inhibit oxidative stress-related proteins such as thioredoxin reductase. Its multifunctiona
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:5/21/2015)... May 21, 2015  When Ryan Rendino ... side of his neck, he figured it ... couple weeks off from weight lifting. ...                               A series of ... referred to Michel Kliot, MD , ...
(Date:5/21/2015)... Research and Markets ( ... "Market Assessment of Respiratory Diagnostics in the ... offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,This research service ... market in the United States ... service provides detailed analysis of the current and ...
(Date:5/21/2015)...  CryoLife, Inc. (NYSE: CRY ), a leading ... and vascular surgery, announced today that its Board of ... second quarter 2015 of $0.03 per share of common ... share will be paid on June 19, 2015 to ... 2015.  The ex-dividend date for the quarterly dividend is ...
Breaking Medicine Technology:Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4United States and Europe Respiratory Diagnostics Market Assessment 2015 2CryoLife Announces Quarterly Cash Dividend for the Second Quarter 2015 2
(Date:5/23/2015)... Manufacturers are now required to produce water heaters with a ... the field agree that the regulation is aimed at manufacturers, ... what miles per gallon is to your car. The higher ... HSPF score has been raised to 8.2, technology has since ... 12. Indeed, the regulation was welcomed by environmentalist, and members ...
(Date:5/23/2015)... 2015 Injury lawyer Steven H. Heisler commented ... by the Maryland legislature but which has not been signed ... passed HB 449 with overwhelming bipartisan support on ... it into law. This bill ensures that fracking is prohibited ... demonstrates the danger of fracking to our water supplies and ...
(Date:5/22/2015)... Mountain Point Medical Center, a campus of Jordan Valley ... May 29, 2015 at 11 a.m., followed by a community ... center, set to officially open on June 1, 2015, is ... , “The opening of Mountain Point Medical Center is an ... said Kent Loosle, CEO of Mountain Point Medical Center. “Mountain ...
(Date:5/22/2015)... May 22, 2015 Omar Ahmad Barrada, ... to participate in the 2015 Congress of Future Medical ... as a gathering of “America’s highest achieving high school ... of healthcare, set new goals and learn better study ... live surgery, during which we can ask the surgeons ...
(Date:5/22/2015)... 2015 Family, friends, students, colleagues, mentors ... oncologist, Dr. LaSalle D. Leffall, on Monday, May 18, ... after Grand Rounds in the hospital’s Tower Auditorium. Leffall’s ... the auditorium, trying to keep the secret. “I’d like ... sees me, he’ll know something is up,” she said. ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Welcomes the Department of Energy’s Water Heater Regulation 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 3Health News:Mountain Point Medical Center, a Campus of Jordan Valley Medical Center, Hosts Ribbon Cutting Ceremony and Community Celebration on Friday, May 29, 2015 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2
... -- Substantial progress has been made over the last 15 ... epilepsy and its complications. Yet this progress in epilepsy ... around the world, including many of the nearly three million ... According to Steven C. Schachter, M.D., president of the American ...
... first indication they understand what 2-D images represent, researchers ... can recognize photographs of other monkeys they know, proving ... figure out if they,ve seen them before, researchers report. ... decipher the two-dimensional nature of a photograph, the scientists ...
... Dec. 4 Yogen Fruz , the world,s leading frozen ... -- Yog-Nog and Mint Chocolate Chip . On ... Fruz stores across North America. Yogen Fruz,s low-calorie Yog-Nog and Mint ... indulge in this holiday season. , "We are always ...
... , ... InhibOx, a leading developer of novel ... MolPort, an innovator in rare chemical trading.,MolPort focuses on developing rare ... we provide this database and its updates to computational chemists at ...
... ... expert to discuss Organizational Transformation through Accountability! , ... Los Angeles, CA (PRWEB) December 4, 2009 -- ... Samuel , best-selling Author, renowned Speaker, and CEO & Founder of IMPAQ Accountability Business ...
... ... is virtually giving away a very popular marketing tool. $1 gets chiropractors 3 months ... templates free of cost. , ... (PRWEB) December 3, 2009 -- Chiropractic Marketing Group announces a ...
Cached Medicine News:Health News:Epilepsy patients caught in treatment gap are not getting state-of-the-art care 2Health News:Epilepsy patients caught in treatment gap are not getting state-of-the-art care 3Health News:Epilepsy patients caught in treatment gap are not getting state-of-the-art care 4Health News:Yogen Fruz Introduces New Holiday Flavors: Yog-Nog and Mint Chocolate Chip 2Health News:InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery 2Health News:InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery 3Health News:Mark Samuel, CEO & Founder, IMPAQ Accountability Business Consultants Inc., to Present at 14th ICF Annual International Conference 2Health News:New Chiropractic Marketing: A $1 Chiropractic Marketing Tool that Can Make Users $1000s 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: